| Literature DB >> 35397430 |
Ping Bai1, Yan Liu1, Yulong Xu1, Robin Striar1, Gengyang Yuan2, Sepideh Afshar2, Amelia G Langan1, Anna K Rattray1, Changning Wang3.
Abstract
The orexin receptors (OXRs) have been involved in multiple physiological and neuropsychiatric functions. Identification of PET imaging probes specifically targeting OXRs enables us to better understand the OX system. Seltorexant (JNJ-42847922) is a potent OX2R antagonist with the potential to be an OX2R PET imaging probe. Here, we describe the synthesis and characterization of [18F]Seltorexant as an OX2R PET probe. The ex vivo autoradiography studies indicated the good binding specificity of [18F]Seltorexant. In vivo PET imaging of [18F]Seltorexant in rodents showed suitable BBB penetration with the highest brain uptake of %ID/cc = 3.4 at 2 min post-injection in mice. The regional brain biodistribution analysis and blocking studies showed that [18F]Seltorexant had good binding selectivity and specificity. However, pretreatment with unlabelled Seltorexant and P-gp competitor CsA observed significantly increased brain uptake of [18F]Seltorexant, indicating [18F]Seltorexant could interact P-gp at the blood-brain barrier. Our findings demonstrated that [18F]Seltorexant is a potential brain OX2R PET imaging probe, which paves the way for new OX2R PET probes development and OX system investigation.Entities:
Keywords: Imaging; Orexin receptors; PET; Radiotracer
Mesh:
Substances:
Year: 2022 PMID: 35397430 PMCID: PMC9050936 DOI: 10.1016/j.bioorg.2022.105779
Source DB: PubMed Journal: Bioorg Chem ISSN: 0045-2068 Impact factor: 5.307